suberic acid

Supramolecules

Namelog KSDpHT(°C)MethodRef
[a-Cyclodextrin](1).[suberic acid] 3.52 3.00 9.0 80.0 electrospray ionization mass spectrometry Valérie Gabelica 2003

succinic acid

Supramolecules

Namelog KSDpHT(°C)MethodRef
[a-Cyclodextrin](1).[succinic acid] 1.81 0.04 7.0 22.0 NMR titration Daniel W. Armstrong 2006
[a-Cyclodextrin](1).[succinic acid] 2.24 1.21 freezing point depression method, osmotic measurements Masahiko Suzuki 1993
[b-Cyclodextrin](1).[succinic acid] 1.33 1.21 7.0 22.0 NMR titration Daniel W. Armstrong 2006
[b-Cyclodextrin](1).[succinic acid] 1.29 0.65 freezing point depression method, osmotic measurements Masahiko Suzuki 1993
[g-Cyclodextrin](1).[succinic acid] 0.82 0.51 7.0 22.0 NMR titration Daniel W. Armstrong 2006
[g-Cyclodextrin](1).[succinic acid] 0.41 -0.22 freezing point depression method, osmotic measurements Masahiko Suzuki 1993
[2-O-(2-Hydroxy)propyl-b-Cyclodextrin](1).[succinic acid] 0.63 0.11 7.0 22.0 NMR titration Daniel W. Armstrong 2006
[Sulfated-b-Cyclodextrin](1).[succinic acid] 1.65 0.88 7.0 22.0 NMR titration Daniel W. Armstrong 2006
[Carboxymethylated-b-Cyclodextrin (DS ~3.5)](1).[succinic acid] 2.43 1.40 7.0 22.0 NMR titration Daniel W. Armstrong 2006

sulfaproxyline

MW HBA HBD LogP CAS Suppliers Supplier IDs Storage ID Quantity Class PAINS
334.39 6 2 4.23 SF_C740 None Not checked

SMILES: CC(C)Oc1ccc(cc1)C(=O)N[S](=O)(=O)c2ccc(N)cc2

Supramolecules

Namelog KSDpHT(°C)MethodRef
[b-Cyclodextrin](1).[sulfaproxyline] 2.97 2.08 7.0 25.0 UV-vis spectroscopy Barbara Szafran 1999

sulfobutylether-b-cyclodextrin

Supramolecules

Namelog KSDpHT(°C)MethodRef
[sulfobutylether-b-cyclodextrin](1).[danazol] 2.48 22.0 phase solubility Moji Christianah Adeyeye 2001
[sulfobutylether-b-cyclodextrin](1).[danazol] 2.20 37.0 phase solubility Moji Christianah Adeyeye 2001
[sulfobutylether-b-cyclodextrin](1).[Ebselen] 3.43 7.0 25.0 phase solubility Kaneto Uekama 2002
[sulfobutylether-b-cyclodextrin](1).[Ebselen] 3.56 7.0 25.0 1H-NMR Kaneto Uekama 2002
[sulfobutylether-b-cyclodextrin](1).[fentanyl] 2.86 8.0 phase solubility J. Plaizier-Vercammen 2003
[sulfobutylether-b-cyclodextrin](1).[Ziprasidone mesylate] 2.98 3.8 CD, NMR, phase solubility Yesook Kim 1998
[sulfobutylether-b-cyclodextrin](1).[dipivefrine] 4.15 5.0 70.0 HPLC-method Pekka Jarho 1997
[sulfobutylether-b-cyclodextrin](1).[dipivefrine] 4.31 5.0 60.0 HPLC-method Pekka Jarho 1997
[sulfobutylether-b-cyclodextrin](1).[dipivefrine] 4.46 5.0 50.0 HPLC-method Pekka Jarho 1997
[sulfobutylether-b-cyclodextrin](1).[dipivefrine] 4.48 5.0 37.0 HPLC-method Pekka Jarho 1997
[sulfobutylether-b-cyclodextrin](1).[dipivefrine] 3.99 7.4 70.0 HPLC-method Pekka Jarho 1997
[sulfobutylether-b-cyclodextrin](1).[dipivefrine] 4.16 7.4 60.0 HPLC-method Pekka Jarho 1997
[sulfobutylether-b-cyclodextrin](1).[dipivefrine] 4.49 7.4 50.0 HPLC-method Pekka Jarho 1997
[sulfobutylether-b-cyclodextrin](1).[dipivefrine] 4.81 7.4 37.0 HPLC-method Pekka Jarho 1997
[sulfobutylether-b-cyclodextrin](1).[neutral red] 2.88 5.0 20.0 Fluorescence spectroscopy Shaomin Shuang 2002
[sulfobutylether-b-cyclodextrin](1).[neutral red] 3.36 7.5 20.0 Fluorescence spectroscopy Shaomin Shuang 2002
[sulfobutylether-b-cyclodextrin](1).[neutral red] 3.41 10.5 20.0 Fluorescence spectroscopy Shaomin Shuang 2002
[sulfobutylether-b-cyclodextrin](1).[chlorambucil] 3.15 1.70 7.35 40.0 HPLC-method Thorsteinn Loftsson 1998
[sulfobutylether-b-cyclodextrin](1).[indomethacin] 2.41 1.30 9.8 40.0 HPLC-method Thorsteinn Loftsson 1998
[sulfobutylether-b-cyclodextrin](1).[diazepam] 1.85 1.78 2.0 30.5 HPLC-method Thorsteinn Loftsson 1998
[sulfobutylether-b-cyclodextrin](1).[naproxen] 3.72 5.0 25.0 UV-vis spectroscopy P. Mura 2005
[sulfobutylether-b-cyclodextrin](1).[naproxen] 3.58 5.0 37.0 UV-vis spectroscopy P. Mura 2005
[sulfobutylether-b-cyclodextrin](1).[naproxen] 3.49 5.0 45.0 UV-vis spectroscopy P. Mura 2005
[sulfobutylether-b-cyclodextrin](1).[R-Apomorphine] 0.21 3.0 25.0 Capillary electrophoresis Ann Van Schepdael 2004
[sulfobutylether-b-cyclodextrin](2).[R-Apomorphine] 0.19 3.0 25.0 Capillary electrophoresis Ann Van Schepdael 2004
[sulfobutylether-b-cyclodextrin](1).[S-Apomorphine] 0.57 3.0 25.0 Capillary electrophoresis Ann Van Schepdael 2004
[sulfobutylether-b-cyclodextrin](2).[S-Apomorphine] 0.60 3.0 25.0 Capillary electrophoresis Ann Van Schepdael 2004
[sulfobutylether-b-cyclodextrin](1).[2,6-diisopropyl phenol] 3.57 7.0 30.0 HPLC-method M.K. Manoj Babu 2004
[sulfobutylether-b-cyclodextrin](1).[2,6-diisopropyl phenol] 3.57 7.0 37.0 HPLC-method M.K. Manoj Babu 2004
[sulfobutylether-b-cyclodextrin](1).[cyclosporin A] 1.34 7.0 25.0 HPLC method Laura Matilainen 2006
[sulfobutylether-b-cyclodextrin](1).[valdecoxib] 3.15 6.8 25.0 UV-vis spectroscopy Tayade Pralhad 2005
[sulfobutylether-b-cyclodextrin](1).[butyl-methoxydibenzoylmethane] 3.34 7.0 25.0 HPLC-method Santo Scalia 2004
[sulfobutylether-b-cyclodextrin](2).[butyl-methoxydibenzoylmethane] 1.08 7.0 25.0 HPLC-method Santo Scalia 2004
[sulfobutylether-b-cyclodextrin](1).[O6-benzylguanine] 2.75 7.0 25.0 HPLC-method Valentino J. Stella 1995
[sulfobutylether-b-cyclodextrin](1).[O6-benzylguanine] 2.53 7.0 50.0 HPLC-method Valentino J. Stella 1995
[sulfobutylether-b-cyclodextrin](1).[O6-benzylguanine] 2.49 2.2 50.0 HPLC-method Valentino J. Stella 1995
[sulfobutylether-b-cyclodextrin](1).[O6-benzylguanine] 2.43 4.8 50.0 HPLC-method Valentino J. Stella 1995
[sulfobutylether-b-cyclodextrin](1).[ozonide antimalarial] 6.36 5.30 7.4 25.0 Isothermal Titration Calorimetry Susan A. Charman 2006
[sulfobutylether-b-cyclodextrin](1).[ozonide antimalarial] 6.20 5.30 7.4 37.0 Isothermal Titration Calorimetry Susan A. Charman 2006
[sulfobutylether-b-cyclodextrin](1).[vinpocetine] 2.53 7.0 21.0 UV-vis spectroscopy Francisco Veiga 2003
[sulfobutylether-b-cyclodextrin](1).[vinpocetine] 2.53 0.90 7.0 22.0 UV-vis spectroscopy Francisco J.B. Veiga 2003
[sulfobutylether-b-cyclodextrin](1).[4[4-(methylsulfonyl) phenyl]-3-phenyl-2 (5H)-furazone] 2.12 7.2 25.0 UV-vis spectroscopy Tayade Pralhad 2004
[sulfobutylether-b-cyclodextrin](1).[3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate] 4.74 2.40 4.0 37.0 Circular dichroism K. Uekama 2001
[sulfobutylether-b-cyclodextrin](1).[3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate] 3.71 2.48 6.0 37.0 Circular dichroism K. Uekama 2001
[sulfobutylether-b-cyclodextrin](1).[3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate] 3.48 2.63 7.4 37.0 Circular dichroism K. Uekama 2001
[sulfobutylether-b-cyclodextrin](1).[amlodipine enantiomer(2)] 2.78 1.85 3.95 17.0 HPLC Anthony F. Fell 1998
[sulfobutylether-b-cyclodextrin](1).[meso-tetrakis(4-N-ethylpyridiumyl) porphyrin] 5.30 7.61 20.0 UV-vis and fluorescence spectroscopy Shuang Shaomin 2005
[sulfobutylether-b-cyclodextrin](1).[meso-tetrakis(4-N-methylpyridiumyl) porphyrin] 4.58 7.61 20.0 UV-vis and fluorescence spectroscopy Shuang Shaomin 2005
[sulfobutylether-b-cyclodextrin](1).[prednisolone] 3.43 1.79 5.5 25.0 NMR spectroscopy Kim L.Larsen 2005
[sulfobutylether-b-cyclodextrin](1).[prednisolone] 3.26 25.0 UV-vis spectroscopy Kim L.Larsen 2005
[sulfobutylether-b-cyclodextrin](1).[6a-methyl prednisolone] 2.85 1.28 5.5 25.0 NMR spectroscopy Kim L.Larsen 2005
[sulfobutylether-b-cyclodextrin](1).[6a-methyl prednisolone] 2.86 25.0 Kim L.Larsen 2005
[sulfobutylether-b-cyclodextrin](1).[6a-methyl prednisolone] 2.86 25.0 UV-vis spectroscopy Kim L.Larsen 2005

sulfobutylether-g-cyclodextrin

Supramolecules

Namelog KSDpHT(°C)MethodRef
[sulfobutylether-g-cyclodextrin](1).[prednisolone] 3.50 1.93 5.5 25.0 NMR spectroscopy Kim L.Larsen 2005
[sulfobutylether-g-cyclodextrin](1).[6a-methyl prednisolone] 3.10 1.59 5.5 25.0 NMR spectroscopy Kim L.Larsen 2005
[sulfobutylether-g-cyclodextrin](1).[6a-methyl prednisolone] 3.12 25.0 Kim L.Larsen 2005